



Q3 2021 Financial Results

Safe Harbor Statement

Certain statements contained in this presentation are "forward-looking statements" about future events and expectations. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, the continuing impact of the COVID-19 outbreak on the economy and our operations (including temporary clinic closures, shortened business hours and reduced patient demand), our failure to develop or acquire company-owned or managed clinics, as rapidly as we intend, our failure to profitably operate company-owned or managed clinics, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage, short-selling strategies and negative opinions posted on the internet which could drive down the market price of our common stock and result in class action lawsuits, and the other factors described in "Risk Factors" in our Annual Report on Form 10-K as filed with the SEC for the year ended December 31, 2020, as updated or revised for any material changes described in any subsequently-filed Quarterly Reports on Form 10-Q or other SEC filings. We anticipate filing our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 on or around November 5, 2021. Words such as, "anticipates," "believes," "continues," "estimates," "espects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "guidance," "forecas

Business Structure

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.



Revolutionizing Access to Chiropractic Care

As an essential healthcare service, The Joint Chiropractic's mission is to improve the quality of life through routine and affordable chiropractic care.

BUILD BRAND



INCREASE AWARENESS



DELIVER EXCEPTIONAL PATIENT EXPERIENCE



OPEN NEW CLINICS





Continued Strength in Third Quarter

37%

Increase in system-wide sales Q3 2021 over Q3 2020

27%

Increase in comp sales¹ for all clinics >13 months in operation Q3 2021 over Q3 2020

21%

Increase in comp sales¹ for all clinics >48 months in operation Q3 2021 over Q3 2020

	Chang	Change from						
	Q3 2021	Q3 2020						
Revenue	\$21.0M	Up 36%						
Op. Income	\$1.3M	\$1.7M						
Net Income	\$1.9M	\$1.6M						
Adjusted EBITDA ²	\$3.3M	Up 25%						
Unrestricted cash \$19 compared to \$20.6M	•	er 30, 2021,						



¹Comparable sales include only the sales from clinics that have been open at least 13 or 48 full months and exclude any clinics that have permanently closed.

² Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.


88 Clinics Opened YTD 2021 Driving to 1,000 Clinics by the End of 2023


	00.000	00 0004
	Q3 2020	Q3 2021
Franchise Licenses Sold	30	44
Total New Franchised Clinics Opened	22	28
Greenfield Clinics Opened	1	5
Franchised Clinics Acquired	0	0
Clinics in Development	218	295






132 Franchise Licenses Sold in YTD 2021







- 82% sold by RDs in 2021
- 70% of clinics supported by 21 RDs at September 30, 2021
- RDs cover 59% of Metropolitan Statistical Areas (MSAs) at September 30, 2021



¹ Of the 1,094 franchise licenses sold as of September 30, 2021, 295 are in active development, 666 are currently operating and the balance represents terminated/closed licenses.

The Joint Corp. | NASDAG: JYNT


Exciting Promotions

Q3 Education Campaign

- Promoting the benefits of chiropractic care for kids
- During Back-to-School season
- Secured 230+ million total media impressions

Q4 Holiday Promotions

- Annual Black Friday package sale
- Year-End membership promotion
- Direct marketing campaigns offer patients with time limited opportunities





The Joint Corp. | NASDAQ: JYNT

Successfully Launched New IT Platform in July 2021

Thank You

To our franchises and clinic users for their enormous effort to make this launch successful.







Q3 2021 Financial Results

\$ in M ¹	Q3 2021	Q3 2020	Differe	ences
Revenue • Corporate clinics • Franchise fees	\$21.0 11.6 9.4	\$15.4 8.4 7.0	\$5.6 3.2 2.4	36% 38% 33%
Cost of revenue	2.3	1.7	0.6	34%
Sales and marketing	2.9	1.8	1.0	56%
Depreciation and amortization	1.7	0.7	0.9	133%
G&A	12.8	9.4	3.4	36%
Operating Income	1.3	1.7	(0.4)	(21)%
Tax Benefit	0.6	(0.1)	0.7	9X
Net Income/(Loss)	1.9	1.6	0.0	21%
Adj. EBITDA ²	3.3	2.6	0.7	25%



¹ Due to rounding, numbers may not add up precisely to the totals.

² Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

YTD Sept. 30, 2021 Financial Results

\$ in M ¹	YTD Sept. 30, 2021	YTD Sept. 30, 2020	Differ	ences		
Revenue	\$58.8 32.5 26.2	\$41.7 22.6 19.1	\$17.1 10.0 7.1	41% 44% 37%		
Cost of revenue	6.1	4.6	1.5	34%		
Sales and marketing	8.5	5.7	2.8	50%		
Depreciation and amortization	4.3	2.1	2.2	107%		
G&A	34.5	26.6	7.9	30%		
Operating Income	5.3	2.7	2.6	97%		
Tax Benefit	1.6	(0.1)	1.8	14X		
Net Income/(Loss)	6.9	2.5	4.4	174%		
Adj. EBITDA ²	10.5	5.4	5.1	95%		

Unrestricted cash \$19.5M at Sept. 30, 2021, compared to \$20.6M at Dec. 31, 2020

² Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.



¹ Due to rounding, numbers may not add up precisely to the totals.

Raising 2021 Guidance

\$ in M	2020 Actual	2021 Low Guidance	2021 High Guidance	Midpoint 2021 vs 2020
Revenues	\$58.7	\$80.0	\$81.0	Up 37%
Adjusted EBITDA ¹	\$9.1	\$13.0	\$14.0	Up 48%
New Franchised Clinic Openings	70	105	115	Up 57%
New Company-owned/Managed Clinics ²	4	25	35	7.5X greater




¹ Reconciliation of Adjusted EBITDA to GAAP earnings is included in the appendix.

The Joint Corp. | NASDAQ: JYNT © 2021 The Joint Corp. All Rights Reserved.

 $^{^{\}rm 2}\,\mbox{Through}$ a combination of both greenfields and buybacks.

Substantial Opportunity for Market Share Growth

- Annual spending on back pain: \$134B¹
- Chiropractic care: \$17.9B²
- Total chains make up ~4% of chiropractic³
- By contrast, dentistry chains (DSOs) account for nearly 12%⁴






¹JAMA US Healthcare spending by Payer and Health Condition, 1996-2016, March 3, 2020 | ² IBIS US Industry Report, Chiropractors in the US, April 2021 | ³ Internal Chiropractic Competitive Analysis, August 2019 | ⁴ Apex Reimbursement Specialists, Inc., 2018

The Joint Corp. | NASDAG: JYNT © 2021 The Joint Corp. All Rights Reserved.

Resilient Business Model Drives Long-term Growth

People will continue to seek more noninvasive, holistic ways to manage their pain.

We'll be there to treat them.





¹ For the period ended Dec. 31, 2020 | ² June 2021 Kentley Insights Chiropractic Care Market Research Report

The Joint Corp. | NASDAG: JYNT

Non-GAAP Measure Definition

This presentation includes non-GAAP financial measures. System-wide sales include sales at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the Company's underlying operating performance and operating trends than GAAP measures alone. Reconciliations of net loss to EBITDA and Adjusted EBITDA are presented where applicable. The Company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The Company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase net gain, gain/(loss) on disposition or impairment, and stock-based compensation expenses.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are frequently used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the Company's financial statements filed with the SEC.



Q3 2021 Segment Results

\$ in 000s




Total Revenues
Total Operating Costs
Operating Income (Loss)
Other Income (Expense), net
Loss Before Income Tax Expense
Total Income Taxes
Net Income (Loss)
Net Interest
Income Taxes
Total Depreciation and Amortization Expense
EBITDA
Stock Based Compensation Exp
Bargain Purchase Gain
Loss on Disposition/Impairment
Acquisition Expenses
Adjusted EBITDA

Corporate Clinics		nchise erations	allocated rporate	The Joint Consolidated				
\$	11,634 (10,393)	\$ 9,351 (5,195)	\$ 7 (4,066)	\$	20,992 (19,653)			
	1,241	 4,157	(4,059)		1,339 (16)			
	1,239	4,157	(4,073)		1,323			
	1,239	 4,157	 (614) (3,459)		(614) 1,937			
	2	-	14		16			
	1,538	165	(614) (41)		(614) 1,662			
	2,779	4,322	(4,101)		3,001			
	-	-	297		297			
	0	-	(4)		(4)			
	2,780	4,322	(3,805)		3,297			

YTD Sept. 30, 2021 Segment Results

\$ in 000s



Total Revenues
Total Operating Costs
Operating Income (Loss)
Other Income (Expense), net
Income (Loss) Before Income Tax Expense
Total Income Taxes
Net Income (Loss)
Net Interest
Income Taxes
Total Depreciation and Amortization Expense
EBITDA
Stock Based Compensation Exp
Bargain Purchase Gain
(Gain) Loss on Disposition/Impairment
Acquisition Expenses
Adjusted EBITDA

Corporate	Franchise	Unallocated	The Joint				
Clinics	Operations	Corporate	Consolidated				
\$ 32,534	\$ 26,214	\$ 10	\$ 58,758				
(28,119)	(14,327)	(10,968)	(53,413)				
4,416	11,887	(10,958)	5,345				
(7)	-	(47)	(54)				
4,409	11,887	(11,004)	5,291				
4,409	11,887	(1,644) (9,360)	(1,644 6,936				
7	-	47 (1,644)	54 (1,644)				
3,880 8,296	166 12,053	(10,728) 827	4,275 9,620 827				
-	-	-	-				
21		(4)	17				
8,316	12,053	48 (9,857)	48 10,513				



GAAP – Non-GAAP Reconciliation

\$ in 000s

	Quarter Ending Quarter Ending Quarter Ending					Qu	arter Ending	g Quarter Ending Quarter Ending Quarter Ending									
		03/31/2020		06/30/2020 09/30/2020			12/3 1/ 2020	03/31/2021			06/30/2021		09/30/2021				
	(21-20	(Q2-20	(Q3-20		Q4-20	FY20	(Q1-21	C	22-21	(23-21		FY21
Total Revenue		13,644		12,590		15,411		17,038	58,683		17,548		20,219		20,992	ļ	58,758
Total Cost of Revenue		1,486		1,368		1,712		1,941	6,507		1,765		2,039		2,300		6,104
Gross Profit	\$	12,158	\$	11,222	\$	13,698	\$	15,097	\$ 52,176	\$	15,783	\$	18,180	\$	18,691	\$	52,654
Sales & Marketing		2,055		1,784		1,846		2,120	7,804		2,489		3,133		2,882		8,504
Depreciation/Amortization Expense		654		693		714		673	2,734		1,170		1,443		1,662		4,275
Other Operating Expenses		8,695		8,487		9,433		9,527	36,142		10,186		11,611		12,812		34,609
Total Other Income (Expense)		(4)		(25)		(26)		(26)	(82)		13		25		(13)		25
Total Income Taxes		(66)		118		76		(7,882)	(7,755)		(364)		(666)		(614)		(1,644)
Net Income (Loss)	\$	815	\$	116	\$	1,604	\$	10,633	\$ 13,167	\$	2,315	\$	2,684	\$	1,937	\$	6,936
Net Interest		4		25		26		24	79		22		16		16		54
Income Taxes		(66)		118		76		(7,882)	(7,755)		(364)		(666)		(614)		(1,644)
Depreciation and Amortization Expense		654		693		714		673	2,734		1,170		1,443		1,662		4,275
EBITDA	\$	1,408	\$	952	\$	2,420	\$	3,447	\$ 8,227	\$	3,142	\$	3,477	\$	3,001	\$	9,620
Stock Based Compensation		250		216		212		207	886		246		284		297		827
Bargain Purchase Gain		-		-		-		-	-		-		-		-		-
(Gain) Loss on Disposition/Impairment		1		(55)		-		2	(51)		65		(44)		(4)		17
Acquisition Expenses		-		-		-		42	42		6		39		3		48
Adjusted EBITDA	\$	1,659	\$	1,113	\$	2,632	\$	3,698	\$ 9,103	\$	3,459	\$	3,756	\$	3,297	\$	10,513



The Joint Corp. Contact Information




Peter D. Holt, President and CEO
peter.holt@thejoint.com
The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



Jake Singleton, CFO
jake.singleton@thejoint.com
The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



Kirsten Chapman, LHA Investor Relations
thejoint@lhai.com
LHA Investor Relations | One Market Street, Spear Tower, Suite 3600, San Francisco, CA 94105 | (415) 433-3777









The Joint Corp. | NASDAG: JYNT